Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468570 · ClinicalTrials.gov registry record
A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 9
- Enrollment target
NCT02468570 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 9 participants.
The verdict
NCT02468570 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.
Interventions
- OTHER Administration of CANTAB and Subject Global Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-08-05 |
| Est. Completion | 2017-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02468570
The ClinicalTrials.gov registry entry for NCT02468570 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Administration of CANTAB and Subject Global Assessment is the first listed.
NCT02468570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02468570 about?
NCT02468570 is a clinical study titled "A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302". A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.
What is the current status of trial NCT02468570?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2015-08-05. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02468570?
The interventions under investigation include: Administration of CANTAB and Subject Global Assessment (OTHER).
Who is sponsoring clinical trial NCT02468570?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.